- Clinical Efficacy and Safety of Naltrexone Combination Therapy in Older Patients with Severe Pruritus
-
Lee J, Shin JU, Noh S, Park CO, Lee KH
- KMID: 2171371
- Ann Dermatol.
- 2016 Apr;28(2):159-163.
- doi: 10.5021/ad.2016.28.2.159
BACKGROUND: Severe pruritus is a challenging condition, and it is more difficult to deal with in older patients due to their limitations in taking oral medication because of underlying diseases,... -
- CITED
-
- Close
- SHARE
-
- Close
- Therapeutic Approach to Pruritus
-
Seo SJ
- KMID: 2347539
- J Korean Med Assoc.
- 2002 Oct;45(10):1251-1258.
- doi: 10.5124/jkma.2002.45.10.1251
Pruritus or itching is an unpleasant sensation well know to all of us which provokes the desire to scratch, usually lasting for minutes in hours and related to cutaneous diseases.... -
- CITED
-
- Close
- SHARE
-
- Close
- Overexpression of Ubiquitin and Amino Acid Permease Genes in Association with Antimony Resistance in Leishmania tropica Field Isolates
-
Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Hajjaran H, Hadighi R, Khamesipour A, Rezaie S, Saffari M, Raoofian R, Heidari M
- KMID: 1715686
- Korean J Parasitol.
- 2013 Aug;51(4):413-419.
- doi: 10.3347/kjp.2013.51.4.413
The mainstay therapy against leishmaniasis is still pentavalent antimonial drugs; however, the rate of antimony resistance is increasing in endemic regions such as Iran. Understanding the molecular basis of resistance... -
- CITED
-
- Close
- SHARE
-
- Close
- Consensus Guidelines for the Treatment of Atopic Dermatitis in Korea (Part I): General Management and Topical Treatment
-
Kim JE, Kim HJ, Lew BL, Lee KH, Hong SP, Jang YH, Park KY, Seo SJ, Bae JM, Choi EH, Suhr KB, Lee SC, Ko HC, Park YL, Son SW, Seo YJ, Lee YW, Cho SH, Park CW, Roh JY
- KMID: 2171457
- Ann Dermatol.
- 2015 Oct;27(5):563-577.
- doi: 10.5021/ad.2015.27.5.563
BACKGROUND: Since the treatment guidelines for atopic dermatitis (AD) were released by the Korean Atopic Dermatitis Association (KADA) work group in 2006, there have been several advances in AD management. OBJECTIVE:... -
- CITED
-
- Close
- SHARE
-
- Close
